Use of spironolactone and indapamide in the treatment of low-renin arterial hypertension

Terapevticheskii Arkhiv

Volumn 78, Issue 2, 2006, Pages 61-64

  Naudzhunas, A ^a   Bagdonas, G ^a   Yankauskene, L ^a   Kazanavichus, G ^a  

^a NONE

Author keywords

Aldosteron; Aldosteron receptors blockers; Diuretic; Low renin arterial hypertension; Renin; Treatment

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; CREATININE; DIURETIC AGENT; INDAPAMIDE; POTASSIUM; RENIN; SODIUM; SPIRONOLACTONE;

ADULT; ARTICLE; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ALDOSTERONE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CREATININE; DIURETICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INDAPAMIDE; MIDDLE AGED; POTASSIUM; RENIN; SODIUM; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 33645100027     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pratt J. H. Low-renin hypertension more common than we think? Cardiol. in Rev. 2000; 8: 202-206.
2. Komiya I., Yamada T., Takara M. et al. Lys 173 Arg and 344T/C Variants of CYP11B2 in Japanese patients with low-renin hypertension. Hypertension 2000; 35: 699-703.
3. Fisher N. D. L., Hurwitz S., Ferri C. et al. Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension 1999; 34: 388-394.
4. Lim P. O., Jung R. T., MacDonald T. M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. J. Clin. Pharmacol. 1999; 48: 756-760.
5. Lim P. O., Jung R. T., MacDonald T. M. Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J. Hum. Hypertens. 2002; 16: 153-158.
6. Benchetrik S., Bernheim J., Podjarny E. Normokalemic hyperaldosteronism in patients with resistant hypertension. I. M. A. J. 2002; 4: 17-20.
7. Connell J. M., Fraser R., Davies E. Disorders of mineralcorticoid synthesis. Best Pract. Res. Clin. Endocrinol. Metab. 2001; 15: 43-60.
8. Booth R. E., Johnson J. P., Stockand J. D. Aldosterone. Advanc. Physiol. Educ. 2002; 26: 8-20.
9. Stewart P. M. Mineralcorticoid hypertension. Lancet 1999; 353: 1341-1348.
10. Stier C. T., Chander P. N., Rocha R. Aldosterone as a medicator in cardiovascular injury. Card. Rev. 2002; 10: 97-107.
11. Pitt B., Zannad F., Remme W. J. et al. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 1999; 341: 709-717.
12. Struthers A. D. Impact of aldosterone on vascular pathophysiology. Congest. Heart Fail. 2002; 8: 8-22.
13. Weber K. T. Cardioreparation in hypertensive heart disease. Hypertension 2001; 38: 588-591.
14. Lim P. O., Struther A. D., MacDonald T. M. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J. Hypertens. 2002; 20: 11-15.
15. Lim P. O., Young W. F., MacDonald T. M. A review of the medical treatment of primary aldosteronism. J. Hypertens. 2001; 19: 353-361.
16. Schwartz G. L., Chapman A. B., Boerwinkle E. et al. Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin. Chem. 2002; 48: 1919-1923.
17. Montori V. M., Young W. F. Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol. Metab. Clin. N. Am. 2002; 31: 619-632.
18. Figuet-Kempt B., Lounay-Mignot P., Bobrie G. et al. Is primary aldosteronism underdiagnosed in clinical practice? Clin. Exp. Pharmacol. Physiol. 2001; 28: 1083-1086.
19. 1999 World Health Organization/International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens. 1999; 17: 151-183.
20. Reyes A. J. Diuretics in the therapy of hypertension. J. Hum. Hypertens. 2002; 16: 578-583.
21. Ouzan J., Perault C., Lincoff A. M. et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. 2002; 15: 339.
22. Ferguson R. K., Turek D. M., Rovner D. R. Spironolactone and hydrochlorthiazide in normal renin and low-renin essential hypertension. Clin. Pharmacol. Ther. 1976; 21: 62-69.
23. Stato A., Suzuki Y., Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens. Res. 1999; 22: 17-22.
24. Torpy D. J., Stratakis C. A., Chrousos G. P. Hyper- and hypoaldosteronism. Vitam. and Horm. 1999; 57: 177-216.